• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ceapro Inc (OP: CRPOF )

N/A UNCHANGED
Last Price Updated: 11:58 AM EDT, May 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ceapro Inc

< Previous 1 2 Next >
Aeterna Zentaris and Ceapro Complete Merger Transaction
June 03, 2024
From Ceapro Inc.
Via GlobeNewswire
Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update
May 29, 2024
From Ceapro Inc.
Via GlobeNewswire
Ceapro Inc. Reports 2023 Financial Results and Operational Highlights
April 29, 2024
From Ceapro Inc.
Via GlobeNewswire
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
March 28, 2024
From Ceapro Inc.
Via GlobeNewswire
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
March 12, 2024
From Ceapro Inc.; Aeterna Zentaris Inc.
Via GlobeNewswire
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
February 26, 2024
From Ceapro Inc.
Via GlobeNewswire
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business
February 23, 2024
From Ceapro Inc.
Via GlobeNewswire
Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris
February 15, 2024
From Ceapro Inc.
Via GlobeNewswire
Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
December 13, 2023
From Ceapro Inc.
Via GlobeNewswire
Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights
November 29, 2023
From Ceapro Inc.
Via GlobeNewswire
Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
November 27, 2023
From Ceapro Inc.
Via GlobeNewswire
Ceapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) Technology
November 07, 2023
From Ceapro Inc.
Via GlobeNewswire
Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update
August 29, 2023
From Ceapro Inc.
Via GlobeNewswire
Ceapro Extends Exclusive International Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise
August 25, 2023
From Ceapro Inc.
Via GlobeNewswire
Ceapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation
July 18, 2023
From Ceapro Inc.
Via GlobeNewswire
Ceapro to Participate in the Virtual Investor Summer Spotlight Series
July 05, 2023
Live moderated video webcast on Wednesday, July 12th at 1:00 PM ET 
From Ceapro Inc.
Via GlobeNewswire
Ceapro Announces Results of 2023 Shareholders’ Meeting
June 07, 2023
From Ceapro Inc.
Via GlobeNewswire
Ceapro Inc. Reports Financial Results for First Quarter 2023 and Provides Corporate Update
May 25, 2023
From Ceapro Inc.
Via GlobeNewswire
Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases
May 23, 2023
From Ceapro Inc.
Via GlobeNewswire
Ceapro Announces Positive Findings Demonstrating Oat Derived Beta Glucan and Avenanthramides Promote Wound Healing and Tissue Regeneration
May 03, 2023
From Ceapro Inc.
Via GlobeNewswire
Ceapro Inc. Appoints Michel Regnier as Senior Vice President, Technical Operations
April 27, 2023
Executive function to oversee Edmonton site technical operations with implementation of Pilot Unit for Pressurized Gas eXpanded (PGX) Technology as key mandate 
From Ceapro Inc.
Via GlobeNewswire
Ceapro Inc. Reports Record 2022 Financial Results and Operational Highlights
April 12, 2023
From Ceapro Inc.
Via GlobeNewswire
Ceapro Announces Data from Research Collaboration with McMaster University to be Presented at the 2023 American Thoracic Society (ATS) International Conference
March 23, 2023
Oral presentation to highlight unique results from pre-clinical studies demonstrating potential of Ceapro’s yeast beta glucan to reprogram macrophages involved in fibrotic lung diseases 
From Ceapro Inc.
Via GlobeNewswire
Ceapro Announces Data from Research Collaboration with the Angiogenesis Foundation to be Presented at the 2023 Annual Meeting of the Wound Healing American Society
March 08, 2023
From Ceapro Inc.
Via GlobeNewswire
Ceapro Inc. Recognized as a Top 50 TSX Venture Exchange Company
February 21, 2023
From Ceapro Inc.
Via GlobeNewswire
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
January 11, 2023
Via ACCESSWIRE
Ceapro to Present at the Virtual Investor 2023 Companies to Watch Event
January 10, 2023
Live video webcast on Wednesday, January 18th at 3:00 PM ET 
From Ceapro Inc.
Via GlobeNewswire
Ceapro Announces Grant of Stock Options
January 04, 2023
From Ceapro Inc.
Via GlobeNewswire
Ceapro Inc. Receives Approval from Health Canada to Commence Phase 1/2a Human Clinical Trial Assessing Avenanthramide Tablets
December 22, 2022
From Ceapro Inc.
Via GlobeNewswire
Ceapro Inc. Reports 2022 Third Quarter and Nine-Month Financial Results and Operational Highlights
November 09, 2022
From Ceapro Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap